Home > Healthcare > Medical Devices > Diagnostic Devices > metabolism assays market
Get a free sample of Metabolism Assays Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Metabolism Assays Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The metabolism assays industry is fragmented in nature, with companies competing to offer superior metabolism assays in this business space. Prominent players such as Merck KGaA, Thermo Fisher Scientific, Inc., Abcam Plc, and Agilent Technologies, Inc. hold a considerable share in this market. These companies are diligently directing their efforts towards continuous innovation to gain substantial market share.
Some of the eminent market participants operating in the metabolism assays industry include:
U.S. metabolism assays industry size is set to surpass USD 1.2 billion by the end of 2032 attributed to the rising prevalence of chronic diseases, supportive government initiatives, and technological advancements among others.
Some of the top metabolism assay companies are Merck KGaA, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Promega Corporation, Kaneka Eurogentec S.A (Kaneka Corporation), RayBiotech Life, Inc., BMG Labtech, and Biotrend Chemikalien GmbH, among others.
Metabolism assays industry from the assay kits & reagents segment generated USD 944.5 million in 2023 and is likely to witness high demand through 2032 owing to its increasing application in studying glucose metabolism, lipid metabolism, enzymatic activities, and other metabolic processes.
Metabolism assays industry size was worth USD 1.5 billion in revenue in 2023 and is projected to exceed USD 2.9 billion by 2032 driven by the rising prevalence of chronic diseases along with the growing demand for personalized medicines.